ADMA Q2 2024 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$107M+78.3% YoY

Gross Profit

$57M53.6% margin

Operating Income

$39M36.6% margin

Net Income

$32M29.9% margin

EPS (Diluted)

$0.13

QoQ Revenue Growth

+30.9%

Cash Flow

Operating Cash Flow

$46M

Free Cash Flow

$44M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$376M

Total Liabilities

$188M

Stockholders' Equity

$188M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$107M	$60M	+78.3%
Gross Profit	$57M	$17M	+244.2%
Operating Income	$39M	-$473,000	+8387.7%
Net Income	$32M	-$6M	+603.2%

Revenue Segments

ADMA BioManufacturing Segment

$106M99%

Plasma Collection Centers Segment

$1M1%

Corporate Segment

$36,0000%

Geographic Segments

United States

$103M96%

International

$4M4%